ベータ
治験レーダーAI
治験 NCT04634643(対象:非アルコール性脂肪性肝疾患 (NAFLD))は募集中です。詳細は治験レーダーのタイル表示と AI 発見ツールで確認するか、ここで質問してください。
フィルター基準に一致する試験が1件見つかりました
タイル表示

Pathogenesis of Pediatric Nonalcoholic Fatty Liver Disease (NAFLD)

募集中
治験(臨床試験)の詳細は主に英語で提供されています。しかし、治験レーダーAIが支援できます!「治験を説明」をクリックして、選択した言語で試験情報を表示し、議論してください。
治験番号 NCT04634643観察研究 臨床試験 で、非アルコール性脂肪性肝疾患 (NAFLD) に関するものです。現在は 募集中 で、2021年6月28日 から開始しています。260 名の参加者 の募集が計画されています。この治験は イェール大学 によって主催され、2026年1月30日 に完了予定です。ClinicalTrials.gov からの最新更新日は 2025年1月27日 です。
概要
The main aim of the study is to discover the mechanisms underlying the pathophysiology of NAFLD in obese youth.
詳細説明
Nonalcoholic fatty liver disease (NAFLD) is the most common hepatic disease in pediatrics, affecting about 30% of obese youth. The term NAFLD defines a wide spectrum of disease severity ranging from simple intrahepatic fat accumulation without liver injury (steatosis) to nonalcoholic steatohepatitis (NASH), fibrosis and cirrhosis.

A 20-year retrospective study has shown that subjects who develop NAFLD during their youth have about 13 times higher mortality rate for end-stage liver disease than healthy subjects of similar age and gender. NAFLD is highly prevalent among Hispanic youth, while non-Hispanic Black (NHB) youth are protected against intrahepatic fat accumulation even in the presence of severe obesity and insulin resistance. Understanding the pathophysiology underlying these differences could shed new light on the mechanisms leading to NAFLD in obese youth.

Preliminary data suggest that Hispanic and NHB obese youth might have a different ability to metabolize carbohydrates (CHO) through glycolysis, with Hispanics showing higher glycolysis than NHB. Therefore, Hispanics might experience a higher rated tricyclic acid cycle (TCA) and hepatic de novo lipogenesis (DNL).

In the present study, the investigators aim to address the following questions:

  1. Is the different susceptibility between Hispanics and NHB in developing NAFLD due to a higher capability of Hispanics to metabolize CHO through glycolysis, TCA cycle and DNL?
  2. Do these metabolic changes anticipate the onset of the disease in Hispanic youth?
  3. Are the higher rates of glycolysis, TCA and DNL driven by high but not pathologic changes in glucose levels over time?

To address these aims, the investigators plan to recruit 30 Hispanics and 30 NHB obese youth and to measure glycolysis by using a new method to assess lactate kinetics and to determine the TCA cycle and DNL by using 13C-Propionate and D2O.

The investigators will also assess glycolysis and intrahepatic fat content in a group of 200Hispanic obese youth without fatty liver at baseline every 12 months for two years to determine whether higher glycolytic rates precede intrahepatic fat accumulation. To assess whether metabolic changes in glycolysis are driven by higher but not-pathologic glucose levels, the investigators will measure glucose changes over ten days every six months by using a continuous glucose monitoring system. If successful, these studies will provide novel insight into the pathogenesis of pediatric NAFLD and will open new avenues to test novel therapeutic approaches.

Study was paused in 2022 and reopened recruitment in November 2023.

公式タイトル

Pathophysiologic Mechanisms Leading to Intrahepatic Fat Accumulation in Obese Youth

疾患/病気
非アルコール性脂肪性肝疾患 (NAFLD)
その他の研究識別子
NCT番号
開始日
2021-06-28
最終更新日
2025-01-27
終了予定日
2026-01-30
目標参加者数
260
試験の種類
観察研究
状況
募集中
群(アーム)/介入
参加グループ/群介入/治療法
該当なし
Usual Diet and Physical Activity
Patients will be followed up to assess the effect of the usual diet and physical activity on development of NAFLD
主要評価項目
評価指標指標の説明時間枠
Lactate synthesis
lactate synthesis will be measured during an oral glucose tolerance test by measuring lactate. Synthetic rates will be measured by using a mathematical model.
60 months
適格基準

対象年齢
小児, 成人
試験の最低年齢
12 Years
対象性別
全て
  • Good general health, taking no medication on a chronic basis;
  • age 12 to 18 years, in puberty (girls and boys: Tanner stage II-V);
  • BMI >85th for obese cohort;

  • Baseline creatinine >1.0 mg; pregnancy;
  • the presence of endocrinopathies (e.g. Cushing syndrome);
  • cardiac or pulmonary or other significant chronic illness;
  • adolescents with a psychiatric disorder or with substance abuse;
  • monogenic obesity syndromes;
  • use of drugs affecting intrahepatic fat content (e.g.; liraglutide, fish oil, etc.).
National Institute on Minority Health and Health Disparities (NIMHD) logoNational Institute on Minority Health and Health Disparities (NIMHD)
試験中央連絡先
連絡先: Ermena REFUGJATI, 2032157119, [email protected]
1 1カ国の場所

Connecticut

Yale New Haven Hospital, New Haven, Connecticut, 06510, United States
Ermena Refugjati, 連絡先, 203-215-7119, [email protected]
Nicola Santoro, MD, PhD, 研究責任者
募集中